Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. · 2023
Read Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management. by Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9857053.txt.
Introduction
Pati and co-authors review links between obesity and cancer, from risk patterns to care. Obesity is tied to breast, colorectal, esophageal, kidney, gallbladder, uterine, pancreatic, and liver cancers. The authors note that about 4–8% of all cancers are attributed to obesity. Excess weight also raises the risk of dying from cancer.
The review searched PubMed and Google Scholar for work on incidence, recurrence, and disease pathways. It reports that excess body fat raises cancer risk by about 17 percent. Diet, exercise, and behavior therapy form the mainstay of weight care. Drugs and weight-loss surgery act faster and may suit some survivors. The authors call for more data on drug and surgical safety in survivors.
Catalog record
| CREATOR | Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management By Sukanya Pati, Wadeed Irfan, Ahmad Jameel, Shahid Ahmed, Rabia K Shahid, Masahito Shimizu, Andrea Manni Published in: Cancers DOI: 10.3390/cancers15020485 ABSTRACT Abstract Simple Summary Obesity has been linked to several common cancers including breast, colorectal, esophageal, kidney, gallbladder, uterine, pancreatic, and liver cancer. Obesity also increases the risk of dying from cancer and may influence the treatment choices. About 4–8% of all cancers are attributed to obesity. The underlying mechanism of obesity causing cancer is complex and is incompletely understood. Lifestyle changes that include diet, exercise, and behavior therapy are the mainstay of interventions. Drug therapy and weight reduction surgery result in a more rapid weight loss and may be used for a subgroup of cancer survivors with obesity. This review highlights the epidemiology and the risk associated with the development and recurrence of cancer in obese individuals and the management of obesity. Abstract Background: Obesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but is also a major risk factor for the development of and mortality related to a subgroup of cancer. This review focuses on epidemiology, the relationship between obesity and the risk associated with the development and recurrence of cancer and the management of obesity. Methods: A literature search using PubMed and Google Scholar was performed and the keywords ‘obesity’ and cancer’ were used. The search was limited to research papers published in English prior to September 2022 and focused on studies that investigated epidemiology, the pathogenesis of cancer, cancer incidence and the risk of recurrence, and the management of obesity. Results: About 4–8% of all cancers are attributed to obesity. Obesity is a risk factor for several major cancers, including post-menopausal breast, colorectal, endometrial, kidney, esophageal, pancreatic, liver, and gallbladder cancer. Excess body fat results in an approximately 17% increased risk of cancer-specific mortality. The relationship between obesity and the risk associated with the development of cancer and its recurrence is not fully understood and involves altered fatty acid metabolism, extracellular matrix remodeling, the secretion of adipokines and anabolic and sex hormones, immune dysregulation, and chronic inflammation. Obesity may also increase treatment-related adverse effects and influence treatment decisions regarding specific types of cancer therapy. Structured exercise in combination with dietary support and behavior therapy are effective interventions. Treatment with glucagon-like peptide-1 analogues and bariatric surgery result in more rapid weight loss and can be considered in selected cancer survivors. Conclusions: Obesity increases cancer risk and mortality. Weight-reducing strategies in obesity-associated cancers are important interventions as a key component of cancer care. Future studies are warranted to further elucidate the complex relationship between obesity and cancer with the identification of targets for effective interventions. Keywords: obesity, cancer, malignancy, overweight, body mass index, epidemiology, cancer outcomes, cancer risk, treatment 1. INTRODUCTION Obesity is a common disease and has been associated with several major chronic illnesses including coronary artery disease, diabetes mellitus, hypertension, osteoarthritis, sleep disorders, and mental illnesses, among others [1,2,3]. More importantly, there is growing evidence that obesity increases the risk of several solid-organ and hematological malignancies [4,5,6,7,8]. Obesity has been linked to cancer of the breast, colon and rectum, esophagus, stomach, gallbladder, uterus, pancreas, and ovary, among others [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]. The relationship between obesity and cancer is rather complex. Obesity is not only associated with an increased risk of cancer but may also increase the risk of cancer recurrence and mortality in cancer survivors [26,27]. Hence, the management of obesity as an early intervention in patients with early-stage cancer is important to improve cancer outcomes. Over the past decade, new evidence of the association between obesity and cancer risk and inferior outcomes has arisen [6,7,8,26,27]. New drugs that are more effective and relatively safer than the older agents have been approved for weight management in adults with obesity [28,29,30]. An increasing number of prospective studies are underway to address various aspects of obesity in cancer patients. This review was undertaken to provide readers updated information on obesity and cancer. The paper first describes the definition of obesity, the epidemiology of obesity and cancer in the general population, the use of new technology in measuring obesity and body fat distribution, and potential biologic mechanisms of the development of cancer in obese individuals. It then reviews recent data on the negative relationship between obesity and cancer outcomes, including the risk of recurrent disease and treatment-related complications. Then, it evaluates the management of obesity using various strategies in cancer survivors where weight reduction is an important adjunct to cancer treatment in reducing the risk of recurrent disease and a new obesity-related primary cancer. It ends with summarizing ongoing clinical trials related to obesity in cancer survivors. 2. METHODS A literature search was performed using PubMed and Google Scholar. In addition, clinical practice guidelines, position papers by professional societies and organizations, and the reference lists of relevant articles were reviewed for identification pertinent articles. Due to the wide scope of this paper, a formal literature search was deemed impractical. The search was mostly limited to papers published in English over the past decade up to September 2022 and was focused on studies that investigated epidemiology, the pathogenesis of cancer in obesity, cancer incidence and the risk of recurrence in obesity, and the management of obesity. As this review addresses several aspects of cancer and obesity, multiple searches using various key words in combination with “obesity” and “cancer” were performed independently to identify key papers relevant to a section. The senior authors reviewed the citations and content of each section and made appropriate changes. Most clinical evidence is derived from meta-analyses and or systematic reviews of observational studies or pooled analyses of clinical trials. 3. DEFINITION AND MEASUREMENT OF OBESITY Obesity is characterized by the presence of excess body fat [1]. “Obese” and “obesity” are the terms used by clinicians to describe those individuals with a substantially increased risk of ill-health due to the accumulation of excessive body fat. Although obesity was recognized as a disease by the World Health Organization (WHO) in the late 1940s, it was only during the latter part of the century that the term became significant, after its connection was established with serious illnesses [31]. The WHO has defined obesity as “abnormal or excessive fat accumulation to the extent that health may be impaired” [1]. It results from a complex interplay between genetic, environmental, socioeconomic, and behavioral factors [32]. Body mass index (BMI) is the surrogate measurement of excess body fatness. Obesity is commonly described as a BMI or weight to height ratio of greater than or equal to 30 kg/m2 [1]. Individuals with a BMI of 25–29 kg/m2 are considered overweight. BMIs > 30 kg/m2 are further classified as follows: class I, a BMI of 30.0–34.9 kg/m2; class II, a BMI of 35.0–39.9 kg/m2; and class III, or extreme obesity, BMI ≥ 40 kg/m2. Obesity is also referred to as a high waist–hip ratio [33,34,35]. Abdominal obesity is defined as a waist–hip ratio above 0.90 in men and above 0.85 in woman [36]. Evidence supports the superiority of a high waist–hip ratio over BMI or waist circumference in predicting